首页|U.S. Food and Drug Administration (FDA) Reports Findings in Artificial Intelligence (Decision region analysis for generalizability of artificial intelligence models: estimating model generalizability in the case of cross-reactivity and ...)
U.S. Food and Drug Administration (FDA) Reports Findings in Artificial Intelligence (Decision region analysis for generalizability of artificial intelligence models: estimating model generalizability in the case of cross-reactivity and ...)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Artificial Intelligence is the subject of a report. According to news reporting originating from Silver Spring, Maryland, by NewsRx correspondents, research stated, “Understanding an artificial intelligence (AI) model’s ability to generalize to its target population is critical to ensuring the safe and effective usage of AI in medical devices. A traditional generalizability assessment relies on the availability of large, diverse datasets, which are difficult to obtain in many medical imaging applications.”
Silver SpringMarylandUnited StatesNorth and Central AmericaArtificial IntelligenceEmerging TechnologiesMachine LearningU.S. Food and Drug Administration
NETL
NSTL
